In Case You Haven’t Noticed: RPC, Inc. (RES), PDL BioPharma, Inc. (PDLI)

A look at its monthly performance shows that RPC, Inc. (NYSE:RES) has recorded a 0.95% gain over the past 30 days. Over the past 12 months the stock has embarked on a drop that has seen it decline -47.28% and is now up by 7.9% since start of this year. The equity price sank -1.3% this week, a trend that has led to both investors and traders taking note of the stock. Its equity price dipped by -28.66% over the past three months which led to its overall six-month decrease to stand at -28.03%.

The shares of RPC, Inc. (RES) dropped by -48.53% or -$10.04 from its last recorded high of $20.69 which it attained on September 03 to close at $10.65 per share. Over the past 52 weeks, the shares of RPC, Inc. has been trading as low as $9.35 before witnessing a massive surge by 13.9% or $1.3. This price movement has led to the RES stock receiving more attention and has become one to watch out for. It dipped by -3.53% on Thursday and this got the market worried. The stock’s beta now stands at 1.02 and when compared to its 200-day moving average and its 50-day moving average, RES price stands -25.74% below and -6.13% below respectively. Its average daily volatility for this week is 3.91% which is less than the 4.91% recorded over the past month.

Experts from research firms are bullish about the near-term performance of RPC, Inc. with most of them predicting a $11.09 price target on a short-term (12 months) basis. The average price target by the analysts will see a 4.13% rise in the stock and would lead to RES’s market cap to surge to $2.24B. The stock has been rated an average 3.4, which roughly stands towards the bearish end of the spectrum. Reuters looked into the 23 analysts that track RPC, Inc. (NYSE:RES) and find out that 14 of them rated it as a Hold. 2 of the 9 analysts rated it as a Buy or a Strong Buy while 7 advised investors to desist from buying the stock or sell it if they already possess it.

A look at RES technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 43.1 point. Its trading volume has lost -315113 shares compared to readings over the past three months as it recently exchanged 1504887 shares. This means there is reduced activity from short-term traders as per session, its average trading volume is 1820000 shares, and this is 0.83 times the normal volume.

The price of PDL BioPharma, Inc. (NASDAQ:PDLI) currently stands at $3.17 after it went down by $-0.05 or -1.55% and has found a strong support at $3.14 a share. If the PDLI price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $3.1 mark would also be bad for the stock as it means that the stock would plunge by 2.21% from its current position. However, if the stock price is able to trade above the resistance point around $3.21, then it could likely surge higher to try and break the upward resistance which stands at $3.25 a share. Its average daily volatility over the past one month stands at 2.8%. The stock has plunged by 0.79% from its 52-weeks high of $3.145 which it reached on May. 02, 2019. In general, it is 29.02% above its 52-weeks lowest point which stands at $2.25 and this setback was observed on Sep. 17, 2018.

Analysts have predicted a price target for PDL BioPharma, Inc. (PDLI) for 1 year and it stands at an average $3/share. This means that it would likely increase by -5.36% from its current position. The current price of the stock has been moving between $3.145 and $3.22. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $3. On the other hand, one analyst is super bullish about the price, setting a target as high as $3.

The PDLI stock Stochastic Oscillator (%D) is at 69.22%, which means that it is currently neutral. The shares P/S ratio stands at 2.03 which compares to the 51.98 recorded by the industry or the 10.06 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 25.56, which is higher than the 0 multiple of 12-month price-earnings (P/E). The company’s earnings have gone down, with a quarterly decrease rate of -13.2% over the past five years.

Analysts view PDL BioPharma, Inc. (NASDAQ:PDLI) as a Buy, with 0 consensus rating. Reuters surveyed 1 analysts that follow PDLI and found that 1 of those analysts rated the stock as a Hold. The remaining 0 were divided, with 0 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying PDL BioPharma, Inc. (PDLI) shares or sell it if they already own it.